Atopic DermatitisFeatured ArticlesThe Latest

Recommendations for Topical AD Management in the Philippines

By January 26, 2021No Comments

Featured Article

Featured Article

Atopic Dermatitis Philipines

The prevalence of atopic dermatitis is increasing in Asia, patients have indicated they are not satisfied with disease control; yet, research indicates they are not correctly applying treatments or they prefer alternative therapies.

The prevalence of atopic dermatitis is increasing in Asia, patients have indicated they are not satisfied with disease control; yet, research indicates they are not correctly applying treatments or they prefer alternative therapies.

Heather Onorati

The prevalence of atopic dermatitis is increasing in Asia, patients have indicated they are not satisfied with disease control; yet, research indicates they are not correctly applying treatments or they prefer alternative therapies.

“AD is considered incurable, thus, there is a need for accepted guidelines to manage and reduce the burden that this condition brings,” write authors of a recent review (“The ABC Topical Management of Atopic Dermatitis in Philippines: Expert Recommendations“) published in the Journal of Drugs in Dermatology. 

Data from 744,673 dermatological consults in the Philippine Dermatological Society-accredited outpatient institutions collected between 2007 and 2011 showed that 65% of patients were children between 1-12 years old and 24% of patients were infants less than one year old. Because children rely on caregivers to administer treatments, disease control depends largely on the education, resources and attitudes toward treatment of the caregivers, the researchers note.

An earlier paper cited by the authors proposed an easy-to-follow ABC scheme based on characteristics of Atopic Dermatitis. In the current review, the authors build on this scheme with their suggestions.

The Anti-inflammatory phase focuses on using topical corticosteroids and/or topical calcineurin inhibitors to control inflammation during flare ups. The authors suggest considering patient characteristics in disease management as well as characteristics of anti-inflammatory agents. They also add, “Monitoring for overt signs of infection is another important focus, as this can further aggravate an AD flare.”

In the Barrier Restoration phase, the focus of treatment is on reestablishing the integrity of the skin barrier and lengthening time between flares.

“Existing AD guidelines have not provided consistent recommendations about the optimal frequency of moisturizer application but recent guidelines state that moisturizers should be prescribed in adequate amounts (ie, minimum of 250g/week, used at least twice daily) even on non-inflamed skin,” the authors note.

Finally, managing patients in the Basic Care phase focuses on maintaining an intact skin barrier through proper skin care, emollient application and avoiding potential irritants and allergans, the authors write.

The panel identified a lack of proper patient and caregiver education regarding chronicity, course, prognosis, and disease avoidance strategies; the inability to identify disease triggers; the absence of definite guidelines on the effective moisturizer amount and frequency of application; and the lack or absence of proper management of microbial colonization as contributing to the challenges of disease management.

“A holistic approach is essential in the success of AD management,” the authors write. “The ABC scheme presents a simple guide on AD management for the healthcare provider based on the key problems in the different phases of the disease.”

Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry

Atopic Dermatitis Resource Center

 

You May Also Like

Journal of Drugs in Dermatology JDD Article About Looking for Curated Atopic Derm Content? We’ve Got You Covered.

Looking for Curated Atopic Derm Content? We’ve Got You Covered!

| Atopic Dermatitis, Featured Articles, Latest News, The Latest | No Comments
Explore JDDonline If you’re on the hunt for expert-led, handpicked resources on atopic dermatitis, you’re in the right place. Whether you're brushing up on the latest treatment insights or looking…
Journal of Drugs in Dermatology JDD Article About Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review of the Literature

Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review of the Literature

| Featured Articles, Latest News, The Latest | No Comments
Could Rituximab Be the Key to Managing Epidermolysis Bullosa Acquisita? Epidermolysis bullosa acquisita (EBA) is a rare and often debilitating autoimmune blistering disease that remains notoriously difficult to manage. While…
Journal of Drugs in Dermatology JDD Article About An Innovative Cream Improves Signs and Symptoms of Dermatoporosis in Patients Aged 65 and Over

An Innovative Cream Improves Signs and Symptoms of Dermatoporosis in Patients Aged 65 and Over

| Featured Articles, Latest News, The Latest | No Comments
A Breakthrough Approach to Aging Skin: Can This Cream Combat Dermatoporosis? As skin ages, it becomes fragile, thin, and prone to bruising - a condition known as dermatoporosis, which is…

Leave a Reply